Terlipressin therapy for moderate-to-severe hyponatraemia in patients with liver failure

Internal Medicine Journal

Volumn 43, Issue 3, 2013, Pages 240-246

  Prakoso, E ^a,b   Jones, C ^a   Koorey, D J ^a   Strasser, S I ^a   Bowen, D ^a,b   McCaughan, G W ^a,b   Shackel, N A ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

Hyponatraemia; Liver failure; Terlipressin

Indexed keywords

SODIUM; TERLIPRESSIN;

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CYANOSIS; DEATH; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; HYPONATREMIA; ISCHEMIC CHEST PAIN; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG EDEMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMACH ULCER; THORAX PAIN;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; HYPONATREMIA; LIVER FAILURE; LYPRESSIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84874395393     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12032     Document Type: Article

References (39)

1. Ginés P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W etal. Hyponatraemia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-864.
2. Angeli P, Wong F, Watson H, Gines P, Capps Investigators. Hyponatraemia in cirrhosis: results of a patient population survey. Hepatology 2006; 44: 1535-1542.
3. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A etal. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495-1501.
4. Guevara M, Baccaro ME, Torre A, Gomez-Anson B, Rios J, Torres F etal. Hyponatraemia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis [see comment]. Am J Gastroenterol 2009; 104: 1382-1389.
5. Jalan R, Elton RA, Redhead DN, Finlayson ND, Hayes PC. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995; 23: 123-128.
6. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39: 464-470.
7. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Rberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation [see comment]. Hepatology 2005; 41: 32-39.
8. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T etal. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660.
9. Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H etal. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-1394.
10. Porcel A, Diaz F, Rendon P, Macias M, Martin-Herrera L, Giron-Gonzalez JA. Dilutional hyponatraemia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-328.
11. Restuccia T, Gomez-Anson B, Guevara M, Alessandria C, Torre A, Alayrach ME etal. Effects of dilutional hyponatraemia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004; 39: 1613-1622.
12. Gines P, Guevara M. Hyponatraemia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008; 48: 1002-1010.
13. Ginès PWF, Smajda Lew E, Diamand F. Hyponatraemia is a major determinant of impaired health-related quality of life in cirrhosis with ascites [Abstract]. Hepatology 2007; 46: 567A.
14. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ etal. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death [see comment]. Hepatology 2004; 40: 802-810.
15. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone [see comment]. Liver Transpl 2005; 11: 336-343.
16. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT etal. Hyponatraemia and mortality among patients on the liver-transplant waiting list [see comment]. N Engl J Med 2008; 359: 1018-1026.
17. Yun BC, Kim WR, Benson JT, Biggins SW, Therneau TM, Kremers WK etal. Impact of pretransplant hyponatraemia on outcome following liver transplantation. Hepatology 2009; 49: 1610-1615.
18. Londono M-C, Guevara M, Rimola A, Navasa M, Taura P, Mas A etal. Hyponatraemia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135-1143.
19. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl 2007; 13: 1115-1124.
20. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D etal. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study [see comment]. Hepatology 2002; 36: 941-948.
21. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM etal. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-48.
22. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008; 103: 1689-1697.
23. Sharma P, Singh S, Sarin SK. Hyponatraemia in patients with acute variceal bleeding treated with terlipressin. Hepatology 2011; 53: 714-14.
24. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G etal. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176.
25. Dunwoodie E, Jowett S. Terlipressin causing a hyponatraemic seizure. Scand J Gastroenterol 2007; 42: 665-665.
26. Escorsell A, Ruiz del Arbol L, Planas R, Albillos A, Banares R, Cales P etal. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 2000; 32: 471-476.
27. Feu F, Ruiz del Arbol L, Banares R, Planas R, Bosch J. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology 1996; 111: 1291-1299.
28. Sola E, Lens S, Guevara M, Martin-Llahi M, Fagundes C, Pereira G etal. Hyponatraemia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 2010; 52: 1783-1790.
29. Martin-Llahi M, Pepin M-N, Guevara M, Diaz F, Torre A, Monescillo A etal. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study [see comment]. Gastroenterology 2008; 134: 1352-1359.
30. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B etal. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome [see comment]. Gastroenterology 2008; 134: 1360-1368.
31. Jalan R, Mookerjee R, Cheshire L, Williams R, Davies N. Albumin infusion for severe hyponatraemia in patients with refractory ascites: a randomized clinical trial. J Hepatol 2007; 46: S95-S95.
32. McCloy R, Baldus W, Maher F, Summerskill WHJ. Effects of changing plasma volume, serum albumin concentration, and plasma osmolality on renal function in cirrhosis. Gastroenterology 1967; 53: 229-239.
33. Kam PCA, Williams S, Yoong FFY. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004; 59: 993-1001.
34. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-156.
35. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-19.
36. Therapondos G, Stanley AJ, Hayes PC. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study. J Gastroenterol Hepatol 2004; 19: 73-77.
37. Krag A, Møller S, Henriksen J, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-1871.
38. Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-59.
39. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther 2006; 24: 935-944.